Condition
ALK
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Not Yet Recruiting3
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07374614Recruiting
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
NCT07235306Phase 2Not Yet Recruiting
Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC
NCT06772610Phase 2Not Yet Recruiting
The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors
NCT06652555Not Yet RecruitingPrimary
The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study
Showing all 4 trials